LifeSpan Vision Ventures recently announced an investment in Matter Bio, a longevity holding company focused on preserving genome integrity. At the center of the company’s philosophy is that as we age, the genome is constantly being damaged by exogenous and endogenous sources.
Errors are occasionally missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. And Matter Bio has assembled a world-class team of scientists and executives to help counter this critical information loss in the genome.
To make this happen, the company has adopted a hub-and-spoke model to advance multiple scientific breakthroughs that each intervene at critical junctures of information loss. And to date, Matter Bio has three companies under its management, with other opportunities in incubation.
Matter Bio expects to initiate clinical trials for one of its programs next year and scale up an already revenue-generating program in the single-molecule mutation sequencing space.
KEY QUOTES:
“Matter Bio continues to progress it’s commercial, clinical and research programs and the proceeds from Lifespan Vision Venture’s investment will support the advancement of the company’s portfolio towards key scientific and commercial milestones.”
— Chris Bradley, CEO of Matter Bio
“Our investment in Matter Bio furthers our mission of supporting companies dedicated to longevity and slowing the key drivers of aging. The company’s business model brings academic expertise, efficiency, and scale to pursue the mission of quantifying and reversing DNA damage to prevent diseases of aging and increase healthy lifespan. We are excited to work with such a talented team of pioneers in the genomic space and look forward to seeing how the company can extend healthspan countering critical information loss in the genome.”
— Dr. Jordan B. Burton, Scientific Analyst at LifeSpan Vision Ventures
